EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Therapeutic Applications of Fibroblast Activation Protein (FAP)-Binding Radiopharmaceuticals: Review of Opportunities and Challenges

Justine Maes iD, Bernard Pôlet, Janke Kleynhans iD, Filip Van Herpe iD, Karolien Goffin iD, Jeroen Dekervel iD, Philippe Nafteux iD, Baki Topal, Frederik Cleeren iD, Christophe M Deroose iD

Cancers · 17.12.2025 · 17 (24) · 4019

DOI: 10.3390/cancers17244019 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 17.12.2025. Verfasst von Justine Maes und 9 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine and Molecular Imaging, Imaging and Pathology, KU Leuven, 3000 Leuven, Belgium. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fonds Wetenschappelijk Onderzoek-Vlaanderen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fibroblast activation protein (FAP)-binding radiopharmaceuticals have emerged as promising candidates for both diagnostic and therapeutic applications in oncology due to their selective targeting of cancer-associated fibroblasts (CAFs). This review evaluates the current literature on the therapeutic use of FAP-targeted radiopharmaceuticals in human studies, with a focus on their safety, efficacy, and clinical applicability. Data on radionuclide type, clinical outcome, radiological and metabolic response and adverse events were extracted and summarized. The included studies demonstrated that lutetium-177,yttrium-90 and actinium-225 (in combination therapy) labeled FAP inhibitors exhibit high tumor uptake, with varying but mostly sufficient retention and a favorable safety profile. While mild adverse events such as fatigue, nausea and grade 1 or 2 hematotoxicity were observed, severe toxicities were rare. FAPI-based radionuclide therapies generally show high disease control rates, with promising results from tandem and combination strategies. The heterogeneity of tumor types and small sample sizes limited the generalizability of findings. FAP-targeted radioligand therapy appears to be a promising treatment option for patients with advanced cancer who have exhausted standard therapies. However, further large-scale, prospective clinical trials are necessary to determine optimal dosing strategies, long-term safety and efficacy across different tumor types. Emerging approaches, such as covalently binding FAP-targeted radiopharmaceuticals and the use of alpha-emitters such as actinium-225, lead-212 and bismuth-213, may further enhance treatment outcomes and warrant future investigation.

Schlagwörter

Stichwörter der Autor:innen

FAPFAPInuclear medicineoncologyradioligand therapyradionuclide therapy

Autor:innen und Institutionen

  • Nuclear Medicine and Molecular Imaging, Imaging and Pathology, KU Leuven, 3000 Leuven, Belgium.
  • Department of Nuclear Medicine, University Hospitals UZ Leuven, 3000 Leuven, Belgium.
  • Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, 3000 Leuven, Belgium.
  • Department of Digestive Oncology, University Hospitals UZ Leuven, 3000 Leuven, Belgium.
  • Department of Thoracic Surgery, University Hospitals UZ Leuven, 3000 Leuven, Belgium.
  • Laboratory of Respiratory Diseases and Thoracic Surgery (BREATHE), Department of Chronic Diseases and Metabolism (CHROMETA), KU Leuven, 3000 Leuven, Belgium.

ORCID-Profile: Justine Maes, Janke Kleynhans, Filip Van Herpe, Karolien Goffin, Jeroen Dekervel, Philippe Nafteux, Frederik Cleeren, Christophe M Deroose

Förderung

  • Fonds Wetenschappelijk Onderzoek-Vlaanderen

Zitieren

APA

Maes, J., Pôlet, B., Kleynhans, J., Van Herpe, F., Goffin, K., Dekervel, J., Nafteux, P., Topal, B., Cleeren, F., & Deroose, C. M. (2025). Therapeutic Applications of Fibroblast Activation Protein (FAP)-Binding Radiopharmaceuticals: Review of Opportunities and Challenges. Cancers, 17(24), 4019. https://doi.org/10.3390/cancers17244019

Vancouver

Maes J, Pôlet B, Kleynhans J, Van Herpe F, Goffin K, Dekervel J, et al. Therapeutic Applications of Fibroblast Activation Protein (FAP)-Binding Radiopharmaceuticals: Review of Opportunities and Challenges. Cancers. 2025;17(24):4019. doi:10.3390/cancers17244019

BibTeX
@article{Maes2025,
  author = {Maes, Justine and Pôlet, Bernard and Kleynhans, Janke and Van Herpe, Filip and Goffin, Karolien and Dekervel, Jeroen and Nafteux, Philippe and Topal, Baki and Cleeren, Frederik and Deroose, Christophe M},
  title = {Therapeutic Applications of Fibroblast Activation Protein (FAP)-Binding Radiopharmaceuticals: Review of Opportunities and Challenges},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {24},
  pages = {4019},
  doi = {10.3390/cancers17244019}
}
Kostenlos starten →